NCPC(SH:600812) Shang Hai Zheng Quan Bao·2025-10-09 18:24Core Viewpoint - The company has provided a guarantee of 170 million yuan for its subsidiary, Jintan Company, to support its operational and strategic needs, which is within the approved limit set by the board and shareholders [2][3][6]. Group 1: Guarantee Details - The guarantee amount for Jintan Company is 17 million yuan, contributing to a total guarantee balance of 48.914 million yuan as of the announcement date [2]. - The company has approved a total guarantee limit of 309.5 million yuan for 2025, with a specific limit of 60 million yuan for Jintan Company [2][3]. Group 2: Financial Metrics - As of June 30, 2025, Jintan Company's debt-to-asset ratio is 31.32%, indicating a relatively stable financial position [4]. - The total external guarantees provided by the company and its subsidiaries amount to 1.701 billion yuan, which is 31.56% of the audited net assets attributable to ordinary shareholders for the year 2024 [7]. Group 3: Board's Opinion - The board unanimously agreed that providing guarantees for subsidiaries is essential for their operational and strategic development, and the associated risks are manageable [6]. Group 4: Recent Developments in Pharmaceutical Sector - The company’s subsidiary, Hebei Huamin Pharmaceutical Co., has received approval for the listing of the antibiotic Cefprozil, enhancing the company's product line [11]. - Cefprozil is effective against various bacterial infections and is expected to contribute positively to the company's portfolio [12].